A recent study from Justin Drake's lab has showed that RET phosphopeptides and mRNA levels are higher in NEPC than in prostate adenocarcinoma, while RET inhibitor AD80 blocks NEPC cell growth in culture and in mouse xenografts (126). This evidence concerns the gene RET and prostate adenocarcinoma.